- Therma Bright (THRM) has announced a C$6M private placement with institutional investors
- The company will use the proceeds for general working capital purposes
- It expects the placement to close on or about February 18, 2022
- Therma Bright is a medical diagnostic and device technology company
- Therma Bright (THRM) is down by 16.67 per cent trading at $0.3125 per share
Therma Bright (THRM) has announced a C$6M private placement with institutional investors.
The company will issue 20M units priced at $0.30 comprised of one common share and one common share purchase warrant.
Each warrant entitles the holder to purchase one common share for $0.375 for five years following the issuance date.
The company will use the proceeds for general working capital purposes.
It expects the placement to close on or about February 18, 2022.
H.C. Wainwright & Co. is acting as the exclusive placement agent.
Therma Bright is a medical diagnostic and device technology company. It developed the AcuVid COVID-19 Rapid Antigen Saliva Test.
Therma Bright (THRM) is down by 16.67 per cent trading at $0.3125 per share as of 12:43 pm EST.